ClinicalTrials.gg
CompletedNCT01976338BlossomUpdated May 8, 2017Results posted

Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)

A Phase 3 interventional study of Ranibizumab 0.5 mg and Sham injection in Macular Edema Secondary to Branch Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 33 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
283
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
14th of 91
283 · median 50
Started
2013
with 9 others
Phase 3
25 of 91
none open now
Registered
52nd of 91
by date
Lead sponsor
21 of 91
Novartis Pharmaceuticals

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 14th largest by enrollment, is one of 10 that started in 2013, is one of 25 in phase 3, and was the 52nd registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO

03

Conditions studied

  • Macular Edema Secondary to Branch Retinal Vein Occlusion

Keywords

  • BRVO
  • macular edema
  • vision impairment
  • retinal vein occlusion
  • ranibizumab
  • branch retinal vein occlusion
  • anti-VEGF therapy
  • RFB002
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with visual impairment secondary to branch retinal vein occlusion (BRVO) with a BCVA between 19 and 73 letters in one eye and at least 35 letters in the other eye.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women or women of child bearing potential without unless using an effective
  • Stroke or myocard infarction within 3 months prior to study
  • History of within the past 5 years
  • Uncontrolled hypertension
  • Active infection or inflammation in any eye
  • use of for at least 30 days in the last 6 months
  • treatment with anti-angiogenic drugs in any eye within last 3 months
  • Panretinal or focal/drid laser photocoagulation within the last few months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
283 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.5 mg

    PRN Intravitreal injection

    Drug: Ranibizumab 0.5 mg

  • Sham comparator
    Sham injection

    As of Month 6 ranibizumab 0.5 mg PRN intravitreal injection

    Other: Sham injection

Interventions

  • intravitreal injection of 0.05 ml

  • OtherSham injection

    Sham intravitreal injection

    Also known as: Sham

06

What researchers measure

Primary outcomes

  1. Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6

    Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 6 and compared to Baseline.

    Time frame: Baseline to Month 1 through Month 6

Secondary outcomes

  1. Average Change of Best Corrected Visual Acuity (BCVA) in Patients From Baseline to Month 1 Through Month 12

    Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 12 and compared to Baseline

    Time frame: Baseline to Month 1 through Month 12

  2. Best Corrected Visual Acuity (BCVA) Change Over Time

    Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 12 and compared to Baseline

    Time frame: Month 1 through Month 12

  3. Number of Participants With a Best Corrected Visual Acuity (BCVA) Improvement of ≥5, ≥10, ≥15, and ≥30 Letters Over Time

    Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters

    Time frame: Baseline to month 12

  4. Number of Participants With Best Corrected Visual Acuity (BCVA)Loss of 15 Letters in the Study Eye

    Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.

    Time frame: Baseline to 12 months

  5. Change in Central-Sub-Field- Thickness (CSFT) Over Time

    OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center

    Time frame: Month 1 to month 12

  6. Change in Total Area of Fluorescein Leakage (Center Subfield) From Baseline Over Time

    Fluorescein leakage area was assessed using Fluorescein angiography (FA) in conjunction with 7-field color fundus photography (CF) at Screening, Month 3, Month 6 and End of Study visit for both eyes

    Time frame: month 3, 6 and 12

  7. Change in Total Area of Fluorescein Leakage (Inner Subfield) From Baseline Over Time

    Fluorescein leakage area was assessed using Fluorescein angiography (FA) in conjunction with 7-field color fundus photography (CF) at Screening, Month 3, Month 6 and End of Study visit for both eyes

    Time frame: Months 3, 6 and 12

  8. Change in Total Area of Fluorescein Leakage (Outer Subfield) From Baseline Over Time

    Fluorescein leakage area was assessed using Fluorescein angiography (FA) in conjunction with 7-field color fundus photography (CF) at Screening, Month 3, Month 6 and End of Study visit for both eyes

    Time frame: Months 3, 6 and 12

  9. Change From Baseline in NEI-VFQ-25 Composite and Subscale Scores at Month 3, Month 6 and Month 12

    The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.

    Time frame: Baseline, months 3, 6 and 12

07

Results

Posted May 8, 2017
Limitations and caveats
One patient was randomized to the ranibizumab group but received no study treatment during the study period and discontinued the study after Visit 2. Therefore, excluded from the Safety set

Participant flow

Participant flow — Overall Study
MilestoneRanibizumab 0.5 mgSham Injection
Started19093
Completed 6 months18591
Discontinued study prior to 6 months52
Completed17789
Not completed134
Withdrew: Physician decision01
Withdrew: Lost to follow-up30
Withdrew: Withdrawal by subject52
Withdrew: Adverse event51

Outcome measures

PrimaryAverage Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6

Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 6 and compared to Baseline.

Time frame:
Baseline to Month 1 through Month 6
Reported as:
Mean · Letters
Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6
LettersRanibizumab 0.5 mgSham Injection
Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 612.5 ± 8.345.0 ± 9.18
Statistical analysis
  • Ranibizumab 0.5 mg vs Sham Injection · Cochran-Mantel-Haenszel · p = <0.001
SecondaryAverage Change of Best Corrected Visual Acuity (BCVA) in Patients From Baseline to Month 1 Through Month 12

Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 12 and compared to Baseline

Time frame:
Baseline to Month 1 through Month 12
Reported as:
Mean · Letters
Average Change of Best Corrected Visual Acuity (BCVA) in Patients From Baseline to Month 1 Through Month 12
LettersRanibizumab 0.5 mgSham Injection
Average Change of Best Corrected Visual Acuity (BCVA) in Patients From Baseline to Month 1 Through Month 1214.0 ± 8.997.7 ± 9.41
SecondaryBest Corrected Visual Acuity (BCVA) Change Over Time

Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 12 and compared to Baseline

Time frame:
Month 1 through Month 12
Reported as:
Mean · Letters
Best Corrected Visual Acuity (BCVA) Change Over Time
LettersRanibizumab 0.5 mgSham Injection
Month 19.5 ± 8.261.7 ± 8.70
Month 211.7 ± 8.393.7 ± 8.81
Month 312.9 ± 8.815.1 ± 10.10
Month 413.4 ± 9.726.0 ± 10.44
Month 513.6 ± 10.246.5 ± 11.53
Month 614.0 ± 10.757.0 ± 12.75
Month 714.7 ± 10.628.5 ± 10.97
Month 814.9 ± 10.5210.4 ± 10.97
Month 914.8 ± 10.4310.3 ± 10.78
Month 1015.8 ± 10.6711.2 ± 11.12
Month 1115.8 ± 10.4211.1 ± 10.48
Month 1216.4 ± 10.9511.3 ± 11.11
SecondaryNumber of Participants With a Best Corrected Visual Acuity (BCVA) Improvement of ≥5, ≥10, ≥15, and ≥30 Letters Over Time

Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters

Time frame:
Baseline to month 12
Reported as:
Number · Participants
Number of Participants With a Best Corrected Visual Acuity (BCVA) Improvement of ≥5, ≥10, ≥15, and ≥30 Letters Over Time
ParticipantsRanibizumab 0.5 mgSham Injection
Month 1 Gain of >=5 letters13933
Month 1 Gain of >=10 letters8612
Month 1 Gain of >=15 letters433
Month 1 Gain of >=30 letters20
Month 2 Gain of >=5 letters15644
Month 2 Gain of >=10 letters11321
Month 2 Gain of >=15 letters726
Month 2 Gain of >=30 letters62
Month 3 Gain of >=5 letters16249
Month 3 Gain of >=10 letters11629
Month 3 Gain of >=15 letters7616
Month 3 Gain of >=30 letters80
Month 4 Gain of >=5 letters15955
Month 4 Gain of >=10 letters12232
Month 4 Gain of >=15 letters8316
Month 4 Gain of >=30 letters112
Month 5 Gain of >=5 letters15960
Month 5 Gain of >=10 letters12740
Month 5 Gain of >=15 letters8319
Month 5 Gain of >=30 letters152
Month 6 Gain of >=5 letters16358
Month 6 Gain of >=10 letters12947
Month 6 Gain of >=15 letters8825
Month 6 Gain of >=30 letters163
Month 7 Gain of >=5 letters16263
Month 7 Gain of >=10 letters13549
Month 7 Gain of >=15 letters9328
Month 7 Gain of >=30 letters163
Month 8 Gain of >=5 letters16866
Month 8 Gain of >=150 letters13052
Month 8 Gain of >=15 letters9433
Month 8 Gain of >=30 letters174
Month 9 Gain of >=5 letters16367
Month 9 Gain of >=10 letters13952
Month 9 Gain of >=15 letters9032
Month 9 Gain of >=30 letters174
Month 10 Gain of >=5 letters16968
Month 10 Gain of >=10 letters14353
Month 10 Gain of >=15 letters9737
Month 10 Gain of >=30 letters227
Month 11 Gain of >=5 letters17267
Month 11 Gain of >=10 letters14156
Month 11 Gain of >=15 letters10336
Month 11 Gain of >=30 letters194
Month 12 Gain of >=5 letters17172
Month 12 Gain of >=10 letters14256
Month 12 Gain of >=15 letters10536
Month 12 Gain of >=30 letters245
SecondaryNumber of Participants With Best Corrected Visual Acuity (BCVA)Loss of 15 Letters in the Study Eye

Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.

Time frame:
Baseline to 12 months
Reported as:
Number · Participants
Number of Participants With Best Corrected Visual Acuity (BCVA)Loss of 15 Letters in the Study Eye
ParticipantsRanibizumab 0.5 mgSham Injection
Month 1, Loss of < 15 letters18889
Month 2, Loss of < 15 letters18990
Month 3, Loss of < 15 letters18988
Month 4, Loss of < 15 letters18988
Month 5, Loss of < 15 letters18988
Month 6, Loss of < 15 letters18889
Month 7, Loss of < 15 letters18891
Month 8, Loss of < 15 letters18892
Month 9, Loss of < 15 letters18793
Month 10, Loss of < 15 letters18892
Month 11, Loss of < 15 letters18793
Month 12, Loss of < 15 letters18791
SecondaryChange in Central-Sub-Field- Thickness (CSFT) Over Time

OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center

Time frame:
Month 1 to month 12
Reported as:
Mean · µm
Change in Central-Sub-Field- Thickness (CSFT) Over Time
µmRanibizumab 0.5 mgSham Injection
Month 1-261.1 ± 171.95-42.4 ± 171.88
Month 2-274.8 ± 174.17-93.1 ± 187.14
Month 3-282.2 ± 175.86-155.3 ± 209.37
Month 4-254.7 ± 183.87-193.2 ± 221.58
Month 5-258.6 ± 180.57-203.2 ± 218.02
Month 6-264.1 ± 168.64-206.6 ± 221.85
Month 7-265.4 ± 179.06-289.8 ± 228.03
Month 8-263.8 ± 179.38-286.1 ± 236.75
Month 9-266.7 ± 182.60-287.9 ± 237.61
Month 10-268.4 ± 173.71-282.9 ± 239.98
Month 11-270.6 ± 184.34-290.3 ± 227.47
Month 12-273.4 ± 184.33-282.9 ± 233.69
SecondaryChange in Total Area of Fluorescein Leakage (Center Subfield) From Baseline Over Time

Fluorescein leakage area was assessed using Fluorescein angiography (FA) in conjunction with 7-field color fundus photography (CF) at Screening, Month 3, Month 6 and End of Study visit for both eyes

Time frame:
month 3, 6 and 12
Reported as:
Mean · mm^2
Change in Total Area of Fluorescein Leakage (Center Subfield) From Baseline Over Time
mm^2Ranibizumab 0.5 mgSham Injection
Month 3-0.400 ± 0.3576-0.026 ± 0.3387
Month 6-0.356 ± 0.3983-0.055 ± 0.4060
Month 12-0.391 ± 0.3716-.0208 ± 0.4075
SecondaryChange in Total Area of Fluorescein Leakage (Inner Subfield) From Baseline Over Time

Fluorescein leakage area was assessed using Fluorescein angiography (FA) in conjunction with 7-field color fundus photography (CF) at Screening, Month 3, Month 6 and End of Study visit for both eyes

Time frame:
Months 3, 6 and 12
Reported as:
Mean · mm^2
Change in Total Area of Fluorescein Leakage (Inner Subfield) From Baseline Over Time
mm^2Ranibizumab 0.5 mgSham Injection
Month 3-1.869 ± 1.80710.111 ± 1.5497
Month 6-1.642 ± 1.9570-0.078 ± 1.6856
Month 12-1.732 ± 1.8059-0.823 ± 1.9650
SecondaryChange in Total Area of Fluorescein Leakage (Outer Subfield) From Baseline Over Time

Fluorescein leakage area was assessed using Fluorescein angiography (FA) in conjunction with 7-field color fundus photography (CF) at Screening, Month 3, Month 6 and End of Study visit for both eyes

Time frame:
Months 3, 6 and 12
Reported as:
Mean · mm^2
Change in Total Area of Fluorescein Leakage (Outer Subfield) From Baseline Over Time
mm^2Ranibizumab 0.5 mgSham Injection
Month 3-4.994 ± 5.4066-0.600 ± 3.6646
Month 6-4.654 ± 5.7504-0.836 ± 4.2819
Month 12-5.078 ± 5.9568-2.797 ± 5.3702
SecondaryChange From Baseline in NEI-VFQ-25 Composite and Subscale Scores at Month 3, Month 6 and Month 12

The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.

Time frame:
Baseline, months 3, 6 and 12
Reported as:
Mean · Scores on a Scale
Change From Baseline in NEI-VFQ-25 Composite and Subscale Scores at Month 3, Month 6 and Month 12
Scores on a ScaleRanibizumab 0.5 mgSham Injection
Change from Baseline at M3 (n=187,91)5.8 ± 10.85-1.1 ± 11.21
Change from Baseline at M6 (n=185,88)7.7 ± 11.880.1 ± 13.95
Change from Baseline at M12 (n=176,88)9.6 ± 13.453.3 ± 13.52

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5 mg—13/190 (6.8%)119/190 (62.6%)
Sham With Ranibizumab 0.5 mg—3/66 (4.5%)46/66 (69.7%)
Sham Without Ranibizumab 0.5 mg—3/26 (11.5%)14/26 (53.8%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventRanibizumab 0.5 mgSham With Ranibizumab 0.5 mgSham Without Ranibizumab 0.5 mg
Coronary artery diseaseCardiac disorders0/1900/661/26
Cholecystitis chronicHepatobiliary disorders0/1900/661/26
Transient ischaemic attackNervous system disorders0/1900/661/26
Macular holeEye disorders0/1901/660/26
ContusionInjury, poisoning and procedural complications0/1901/660/26
Humerus fractureInjury, poisoning and procedural complications0/1901/660/26
Joint dislocationInjury, poisoning and procedural complications0/1901/660/26
Ulna fractureInjury, poisoning and procedural complications0/1901/660/26
Cluster headacheNervous system disorders0/1901/660/26
HypertensionVascular disorders0/1901/660/26
Most frequent other events
Showing 10 of 101
Most frequent other events
EventRanibizumab 0.5 mgSham With Ranibizumab 0.5 mgSham Without Ranibizumab 0.5 mg
HypertensionVascular disorders16/1908/664/26
NasopharyngitisInfections and infestations23/1908/663/26
CoughRespiratory, thoracic and mediastinal disorders9/1902/663/26
Conjunctival haemorrhageEye disorders20/1904/660/26
Spinal osteoarthritisMusculoskeletal and connective tissue disorders2/1900/662/26
HeadacheNervous system disorders11/1902/660/26
Eye painEye disorders10/1901/660/26
Upper respiratory tract infectionInfections and infestations10/1901/661/26
Intraocular pressure increasedInvestigations10/1901/660/26
Retinal haemorrhageEye disorders3/1903/660/26

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ranibizumab 0.5 mgSham InjectionTotal
Mean57.0 ± 10.1456.8 ± 10.0356.9 ± 10.09
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.5 mgSham InjectionTotal
Female10138139
Male8955144
08

Study locations

33 sites
  • Novartis Investigative Site
    Beijing, Beijing 100191, China
  • Novartis Investigative Site
    Beijing, Beijing 100730, China
  • Novartis Investigative Site
    Chongqing, Chongqing 400042, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510060, China
  • Novartis Investigative Site
    Shantou, Guangdong 515041, China
  • Novartis Investigative Site
    Harbin, Heilongjiang 150001, China
  • Novartis Investigative Site
    Wuhan, Hubei 430070, China
  • Novartis Investigative Site
    Changsha, Hunan 410011, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210006, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
  • Novartis Investigative Site
    Nantong, Jiangsu 226000, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Qingdao, Shandong 266011, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Tianjin, Tianjin 300020, China
  • Novartis Investigative Site
    Tianjin, Tianjin 300070, China
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325027, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Beijing, 100176, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Chongqing, 400038, China
  • Novartis Investigative Site
    Shanghai, 200080, China
  • Novartis Investigative Site
    Shanghai, 200092, China
  • Novartis Investigative Site
    Hongkong, Hong Kong
  • Novartis Investigative Site
    Bandung, Jawa Barat 40117, Indonesia
  • Novartis Investigative Site
    Jakarta, 10430, Indonesia
  • Novartis Investigative Site
    Manila, Metro Manila 1000, Philippines
  • Novartis Investigative Site
    San Juan City, 1500, Philippines
  • Novartis Investigative Site
    Kaohsiung, 83301, Taiwan
  • Novartis Investigative Site
    Lin-Kou, 33305, Taiwan
  • Novartis Investigative Site
    Taipei, Taiwan
  • Novartis Investigative Site
    Hanoi, 10000, Vietnam
  • Novartis Investigative Site
    Ho Chi Minh City, 70000, Vietnam
09

References and documents

Publications

  • Wei W, Weisberger A, Zhu L, Cheng Y, Liu C; BLOSSOM Study Group. Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study. Ophthalmol Retina. 2020 Jan;4(1):57-66. doi: 10.1016/j.oret.2019.08.001. Epub 2019 Aug 13. PubMed 31902472 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Mar 2016, 28 months.

Results were first posted in May 2017, 1 year 1 month after primary completion.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 28 months is above that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2013
First posted
Nov 5, 2013
StartActual
Nov 12, 2013
Primary completionActual
Mar 28, 2016
CompletionActual
Mar 28, 2016
Results first posted
May 8, 2017
Last update
May 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01976338
Responsible party
Sponsor
First posted
Nov 5, 2013
Start date
Nov 12, 2013
Primary completion
Mar 28, 2016
Completion
Mar 28, 2016
Results posted
May 8, 2017
Last update
May 8, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion